177 related articles for article (PubMed ID: 37967656)
1. Altering distribution profile of palbociclib by its prodrugs.
Järvinen J; Montaser AB; Adla SK; Leppänen J; Lehtonen M; Vellonen KS; Laitinen T; Jalkanen A; Elmquist WF; Timonen J; Huttunen KM; Rautio J
Eur J Pharm Sci; 2024 Jan; 192():106637. PubMed ID: 37967656
[TBL] [Abstract][Full Text] [Related]
2. Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model.
Parrish KE; Pokorny J; Mittapalli RK; Bakken K; Sarkaria JN; Elmquist WF
J Pharmacol Exp Ther; 2015 Nov; 355(2):264-71. PubMed ID: 26354993
[TBL] [Abstract][Full Text] [Related]
3. L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery.
Puris E; Gynther M; Huttunen J; Auriola S; Huttunen KM
Eur J Pharm Sci; 2019 Mar; 129():99-109. PubMed ID: 30625368
[TBL] [Abstract][Full Text] [Related]
4. L-type amino acid transporter 1 utilizing prodrugs: How to achieve effective brain delivery and low systemic exposure of drugs.
Puris E; Gynther M; Huttunen J; Petsalo A; Huttunen KM
J Control Release; 2017 Sep; 261():93-104. PubMed ID: 28662899
[TBL] [Abstract][Full Text] [Related]
5. Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice.
Biali ME; Auvity S; Cisternino S; Smirnova M; Hacker M; Zeitlinger M; Mairinger S; Tournier N; Bauer M; Langer O
Mol Pharm; 2023 Nov; 20(11):5877-5887. PubMed ID: 37883694
[TBL] [Abstract][Full Text] [Related]
6. (18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.
Liow JS; Zoghbi SS; Hu S; Hall MD; Hines CS; Shetty HU; Araneta MD; Page EM; Pike VW; Kreisl WC; Herscovitch P; Gottesman MM; Theodore WH; Innis RB
Neuroimage; 2016 Sep; 138():134-140. PubMed ID: 27211474
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic Study on the Use of the l-Type Amino Acid Transporter 1 for Brain Intracellular Delivery of Ketoprofen via Prodrug: A Novel Approach Supporting the Development of Prodrugs for Intracellular Targets.
Puris E; Gynther M; de Lange ECM; Auriola S; Hammarlund-Udenaes M; Huttunen KM; Loryan I
Mol Pharm; 2019 Jul; 16(7):3261-3274. PubMed ID: 31180686
[TBL] [Abstract][Full Text] [Related]
8. Central Nervous System Distribution of Panobinostat in Preclinical Models to Guide Dosing for Pediatric Brain Tumors.
Zhang W; Oh JH; Zhang W; Rathi S; Larson JD; Wechsler-Reya RJ; Sirianni RW; Elmquist WF
J Pharmacol Exp Ther; 2023 Dec; 387(3):315-327. PubMed ID: 37827699
[TBL] [Abstract][Full Text] [Related]
9. L-Type Amino Acid Transporter 1 Enables the Efficient Brain Delivery of Small-Sized Prodrug across the Blood-Brain Barrier and into Human and Mouse Brain Parenchymal Cells.
Montaser AB; Järvinen J; Löffler S; Huttunen J; Auriola S; Lehtonen M; Jalkanen A; Huttunen KM
ACS Chem Neurosci; 2020 Dec; 11(24):4301-4315. PubMed ID: 33228353
[TBL] [Abstract][Full Text] [Related]
10. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.
Agarwal S; Sane R; Ohlfest JR; Elmquist WF
J Pharmacol Exp Ther; 2011 Jan; 336(1):223-33. PubMed ID: 20952483
[TBL] [Abstract][Full Text] [Related]
11. Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery.
Peura L; Malmioja K; Laine K; Leppänen J; Gynther M; Isotalo A; Rautio J
Mol Pharm; 2011 Oct; 8(5):1857-66. PubMed ID: 21770378
[TBL] [Abstract][Full Text] [Related]
12. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
[TBL] [Abstract][Full Text] [Related]
13. Dual Modulation of Human P-Glycoprotein and ABCG2 with Prodrug Dimers of the Atypical Antipsychotic Agent Paliperidone in a Model of the Blood-Brain Barrier.
Bohn K; Lange A; Chmielewski J; Hrycyna CA
Mol Pharm; 2017 Apr; 14(4):1107-1119. PubMed ID: 28264565
[TBL] [Abstract][Full Text] [Related]
14. A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration.
Gonçalves J; Silva S; Gouveia F; Bicker J; Falcão A; Alves G; Fortuna A
Int J Pharm; 2021 Jan; 593():120161. PubMed ID: 33307160
[TBL] [Abstract][Full Text] [Related]
15. Targeted efflux transporter inhibitors - A solution to improve poor cellular accumulation of anti-cancer agents.
Huttunen J; Gynther M; Huttunen KM
Int J Pharm; 2018 Oct; 550(1-2):278-289. PubMed ID: 30149128
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine.
Peura L; Malmioja K; Huttunen K; Leppänen J; Hämäläinen M; Forsberg MM; Gynther M; Rautio J; Laine K
Pharm Res; 2013 Oct; 30(10):2523-37. PubMed ID: 24137801
[TBL] [Abstract][Full Text] [Related]
17. Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
Wang T; Agarwal S; Elmquist WF
J Pharmacol Exp Ther; 2012 May; 341(2):386-95. PubMed ID: 22323823
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier.
Zhao R; Raub TJ; Sawada GA; Kasper SC; Bacon JA; Bridges AS; Pollack GM
Drug Metab Dispos; 2009 Jun; 37(6):1251-8. PubMed ID: 19273529
[TBL] [Abstract][Full Text] [Related]
19. Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in rats.
Mairinger S; Hernández-Lozano I; Filip T; Sauberer M; Löbsch M; Stanek J; Wanek T; Sake JA; Pekar T; Ehrhardt C; Langer O
J Control Release; 2022 Sep; 349():109-117. PubMed ID: 35798092
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib.
de Gooijer MC; Zhang P; Thota N; Mayayo-Peralta I; Buil LC; Beijnen JH; van Tellingen O
Invest New Drugs; 2015 Oct; 33(5):1012-9. PubMed ID: 26123925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
